Research ArticleCancer

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

See allHide authors and affiliations

Science Translational Medicine  11 Mar 2020:
Vol. 12, Issue 534, eaaw8275
DOI: 10.1126/scitranslmed.aaw8275

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

BETting on combination treatment

MYCN is a well-known oncogene that plays a role in cancer aggressiveness, but it is typically associated with neuroendocrine cancers. Schafer et al. found a role for MYCN in triple-negative breast cancer, a particularly aggressive form of the disease, and identified a potential intervention. Although there is no standard way to target MYCN directly, the authors determined that a group of experimental drugs called BET inhibitors are effective against triple-negative breast cancers that overexpress MYCN, especially when coupled with the inhibition of MEK, another known oncogene.

View Full Text

Stay Connected to Science Translational Medicine